Pancreatic Cancer Research

ResearcherSecond Affiliated Hospital of Zhejiang UniversityActive in the last 2 years

Xiao Zhi

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5101045242, A5109542360. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 8

  1. Corrigendum to Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci211838↗
  2. Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci187024↗
  3. Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis. Co-author DOI 10.1136/jitc-2021-004129↗
  4. Genome-wide profiling of circulating tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver metastasis. Co-author DOI 10.1002/1878-0261.12757↗
  5. Delivery of miR-212 by chimeric peptide-condensed supramolecular nanoparticles enhances the sensitivity of pancreatic ductal adenocarcinoma to doxorubicin. Co-author DOI 10.1016/j.biomaterials.2018.11.035↗
  6. USP9X inhibition improves gemcitabine sensitivity in pancreatic cancer by inhibiting autophagy. Co-author DOI 10.1016/j.canlet.2018.08.010↗
  7. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo. Co-author DOI 10.18632/oncotarget.4579↗
  8. Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1α-VEGF mediated angiogenesis. First author DOI 10.1016/j.canlet.2014.09.048↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tingbo Liang · 7 shared papers, 2014–2025 · strength 0.66
  2. Mao Ye · 2 shared papers, 2025–2026 · strength 0.37
  3. Xiongbin Lu · 2 shared papers, 2025–2026 · strength 0.37
  4. Kang Sun · 2 shared papers, 2025–2026 · strength 0.37
  5. Jinyuan Song · 2 shared papers, 2025–2026 · strength 0.37
  6. Mengyi Lao · 2 shared papers, 2025–2026 · strength 0.37
  7. Xueli Bai · 4 shared papers, 2014–2025 · strength 0.35
  8. Tao Ma · 3 shared papers, 2018–2020 · strength 0.25
  9. Tingbo Liang · 1 shared paper, 2026 · strength 0.20
  10. Hanshen Yang · 1 shared paper, 2025 · strength 0.17
  11. Xiang Li · 1 shared paper, 2025 · strength 0.17
  12. Lihong He · 1 shared paper, 2025 · strength 0.17
  13. Lingyue Liu · 1 shared paper, 2025 · strength 0.17
  14. Zhengtao Hong · 1 shared paper, 2022 · strength 0.16
  15. Gang Zhang · 1 shared paper, 2022 · strength 0.16
  16. Junming Huang · 1 shared paper, 2022 · strength 0.16
  17. Xing Huang · 1 shared paper, 2022 · strength 0.16
  18. Tianyu Tang · 1 shared paper, 2022 · strength 0.16
  19. Jian Zhang · 1 shared paper, 2020 · strength 0.09
  20. Tao Wei · 1 shared paper, 2020 · strength 0.09
  21. Qi Chen · 1 shared paper, 2020 · strength 0.09
  22. Xiang Li · 1 shared paper, 2020 · strength 0.09
  23. Qi Zhang · 1 shared paper, 2020 · strength 0.09
  24. Wei Chen · 1 shared paper, 2020 · strength 0.09
  25. Risheng Que · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.